Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24730512 | 1.00 | CYP1A2 (0.47) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL25808898 | 1.00 | CYP1A2 (0.47) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL22062834 | 0.94 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL20028722 | 0.94 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL19165618 | 0.94 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL20711713 | 0.86 | CHRNA3 (0.39) | CHRNB4CHRNA3 | |
| SCHEMBL23868163 | 0.86 | CHRNA3 (0.39) | CHRNB4CHRNA3 | |
| SCHEMBL24578065 | 0.83 | CYP1A2 (0.46) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL14169495 | 0.81 | — | — | |
| SCHEMBL25907251 | 0.79 | CHRNB4 (0.43) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022247770-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海璎黎药业有限公司 | 2022-12-01 | — | — | WO | disclosed |
| WO-2021031952-A1 | OXYGEN-SUBSTITUTED SIX-MEMBERED RING PYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | CYP1A2 1713/4885CHRNB4 4497/4885CHRNA3 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.